Congress recently increased annual funding for research on Lyme and related tickborne diseases at NIH by $29 million to a total of $63 million. Most of this is discretionary, although $10 million of it is mandatory for research specific to Lyme disease. In addition to this historic increase, there are opportunities for funding and research support for studies on maternal-fetal transmission of Lyme disease and the impact of pregnancy on immune response. To stimulate researcher interest, NIH has issued a series of notices to encourage investigators to apply for grants and has asked stakeholder organizations for help getting the word out.
Researchers, Eugene Merzon, et al. have published findings from a recent study examining correlations between the use of aspirin for the primary prevention of cardiovascular disease and the lower likelihood of COVID‐19 infection in The FEBS Journal.
Pfizer has received priority review for their vaccine, TicoVac, that protects against tick-borne encephalitis. This tick-borne virus can cause meningitis and trigger long-term neurological symptoms. If approved, the vaccine would potentially protect travelers as well as members of the US military that are deployed to regions where the virus is common, such as Europe and parts of Asia.
In this newly published review, authors address the geographic distribution of the human-infecting Babesia spp., their phylogenetic relationship, and their tick vector worldwide. Authors found that the number of human Babesiosis cases appearing in the literature has increased exponentially in the last 10 years, with the US leading the world in reported case numbers.
Valneva and Pfizer announced that they have initiated a Phase 2 study for their Lyme disease vaccine candidate. This new study builds on previous studies, including new dose regimens as well as being the first clinical study to include children between the ages 5-17 years.
A peer-reviewed report co-authored by Melissa C Fesler and Raphael B Stricker has been published in the International Journal of General Medicine which evaluates pre-exposure prophylaxis (PrEP) using medications approved for use in pregnant women to prevent gestational problems and severe illness in this high-risk population.
As part of the LymeX public-private partnership between Health & Human Services (HHS) and the Cohen Foundation, HHS has published an RFI in the Federal Register, 2.11.21 that seeks information on the current state of the science and technology to accelerate “innovative solutions” for Lyme disease diagnosis. The RFI contains a series of questions it […]
“Diagnosis, Treatment, and Prevention Practices for Lyme Disease by Clinicians, United States, 2013-2015” by Alyssa R. Beck, MPH, Grace E. Marx, MD, and Alison F. Hinckley, PhD, published in Public Health Report, February 4, 2021, presented a study the objective of which “was to better understand factors associated with clinical practices related to tick bites […]
A study by Mikhail et al in Open Forum Infectious Diseases, Feb. 2021, from 2006 to 2017 showed 19,469 beneficiaries had babesiosis recorded, a substantial increase. The highest states by rates were Massachusetts (62), Rhode Island (61), Connecticut (51), New York (30), and New Jersey (19). States previously considered nonendemic saw increases: New Hampshire, Maine, […]
According to the US Department of Agriculture, USDA, the most recent tick to come into the US is now found in 15 states. The information is published in the USDA’s National Haemaphysalis longicornis Situation Report, February 3, 2021. States are VA, WVA, PA, NC, NJ, TN, NY, KY, MD, CT DE, SC, AR, OH, RI. For […]